Thomas Albrecht1,2, Beatrix Schnorr3, Maren Kutschera3, Matthias W Waliszewski4,5. 1. Department of Radiology and Interventional Therapy, Neukölln Vascular Centre, Vivantes Hospital Neukölln, Berlin, Germany. Thomas.albrecht@vivantes.de. 2. Institut für Radiologie und Interventionelle Therapie, Vivantes Klinikum Neukölln, Rudower Str. 48, 12351, Berlin, Germany. Thomas.albrecht@vivantes.de. 3. Experimental Radiology, Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 4. Medical Scientific Affairs, B. Braun Melsungen AG, Berlin, Germany. 5. Department of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
Abstract
PURPOSE: In view of a recent meta-analysis reporting increased mortality following angioplasty with paclitaxel-coated devices in peripheral arteries, we performed a patient-level 2-year mortality analysis based on pooled original data of four randomized controlled trials (THUNDER, FEMPAC, PACIFIER and CONSEQUENT). METHODS AND RESULTS: Clinical data of four randomized controlled trial were pooled to assess 2-year mortality following paclitaxel-coated balloon (PCB) angioplasty compared to angioplasty without paclitaxel (control group). A logistic regression model was applied to identify potential predictors of mortality. At two years, 13 of 185 (7.0%) patients had died in the control group and 16/184 (8.7%) in the PBC group, p = 0.55. Kaplan-Meier analysis revealed no significant difference from all-cause death at 2 years (log rank p = 0.54). Causes of death were well balanced between the groups with no pattern or trend in favour of any specific causes in the PBC group. Logistic regression revealed that treatment groups (controls or PBC) were not a predictor of 2-year mortality. The only predictor for mortality was patient age ≥ 75 years. The delivered paclitaxel doses per patient were not significantly different in patients that died and those who did not die during the 24-month follow-up (5.300 ± 4.224 μg vs. 6.248 ± 4.629 μg, p = 0.433). CONCLUSIONS: Based on original patient-level data of four pooled randomized controlled trials, we found no increase in 2-year mortality in patients treated with PCB compared to control patients treated with uncoated balloons. Causes of death were well balanced between PCB and control patients.
RCT Entities:
PURPOSE: In view of a recent meta-analysis reporting increased mortality following angioplasty with paclitaxel-coated devices in peripheral arteries, we performed a patient-level 2-year mortality analysis based on pooled original data of four randomized controlled trials (THUNDER, FEMPAC, PACIFIER and CONSEQUENT). METHODS AND RESULTS: Clinical data of four randomized controlled trial were pooled to assess 2-year mortality following paclitaxel-coated balloon (PCB) angioplasty compared to angioplasty without paclitaxel (control group). A logistic regression model was applied to identify potential predictors of mortality. At two years, 13 of 185 (7.0%) patients had died in the control group and 16/184 (8.7%) in the PBC group, p = 0.55. Kaplan-Meier analysis revealed no significant difference from all-cause death at 2 years (log rank p = 0.54). Causes of death were well balanced between the groups with no pattern or trend in favour of any specific causes in the PBC group. Logistic regression revealed that treatment groups (controls or PBC) were not a predictor of 2-year mortality. The only predictor for mortality was patient age ≥ 75 years. The delivered paclitaxel doses per patient were not significantly different in patients that died and those who did not die during the 24-month follow-up (5.300 ± 4.224 μg vs. 6.248 ± 4.629 μg, p = 0.433). CONCLUSIONS: Based on original patient-level data of four pooled randomized controlled trials, we found no increase in 2-year mortality in patients treated with PCB compared to control patients treated with uncoated balloons. Causes of death were well balanced between PCB and control patients.
Entities:
Keywords:
Drug-coated balloon angioplasty; Femoro-popliteal lesions; Mortality; Paclitaxel; Pooled data analyses
Authors: Sabine Steiner; Andrej Schmidt; Thomas Zeller; Gunnar Tepe; Marcus Thieme; Lars Maiwald; Henrik Schröder; Wulf Euringer; Matthias Ulrich; Klaus Brechtel; Steffen Brucks; Erwin Blessing; Johannes Schuster; Ralf Langhoff; Sebastian Schellong; Norbert Weiss; Dierk Scheinert Journal: Eur Heart J Date: 2020-07-14 Impact factor: 29.983
Authors: John A Laird; Peter A Schneider; Michael R Jaff; Marianne Brodmann; Thomas Zeller; D Chris Metzger; Prakash Krishnan; Dierk Scheinert; Antonio Micari; Hong Wang; Michele Masters; Gunnar Tepe Journal: Circ Cardiovasc Interv Date: 2019-06-14 Impact factor: 6.546
Authors: Michael D Dake; Gary M Ansel; Marc Bosiers; Andrew Holden; Osamu Iida; Michael R Jaff; Aaron E Lottes; Erin E O'Leary; Alan T Saunders; Marc Schermerhorn; Hiroyoshi Yokoi; Thomas Zeller Journal: Cardiovasc Intervent Radiol Date: 2019-09-09 Impact factor: 2.740
Authors: Peter A Schneider; Marianne Brodmann; Laura Mauri; John Laird; Yoshimitsu Soga; Antonio Micari; Gary Ansel; Mehdi H Shishehbor; Prakash Krishnan; Qi Gao; Kenneth Ouriel; Thomas Zeller Journal: Catheter Cardiovasc Interv Date: 2020-08-24 Impact factor: 2.692
Authors: Vassilios S Vassiliou; Simon C Eccleshall; Ioannis Merinopoulos; Tharusha Gunawardena; Upul Wickramarachchi; Paul Richardson; Clint Maart; Sulfi Sreekumar; Chris Sawh; Trevor Wistow; Toomas Sarev; Alisdair Ryding; Tim Gilbert; Aris Perperoglou Journal: Clin Res Cardiol Date: 2020-09-02 Impact factor: 5.460